Immune Cell Therapy Drugs Market Size, Share, and Industry Analysis By Drug (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Sipuleucel-T, Idecabtagene Vicleucel Lisocabtagene Maraleucel, Tisagenlecleucel, Lifileucel, and Others), By Indication (Lymphoma, Myeloma, Leukemia, and Others), By End-user (Hospitals and Oncology Treatment Centers), and Regional Forecast, 2026-2034

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
   4. Market Trends
4. Key Insights
   1. Prevalence of Key Diseases, By Key Countries/Region, 2023
   2. Key Industry Developments (Mergers, Acquisitions & Partnerships, etc.), By Key Players
   3. Pipeline Analysis, By Key Players
   4. New Product Launches/Approvals, By Key Players
   5. Technological Advancements in Immune Cell Therapy Drugs Market
   6. Impact of COVID-19 on the Market
5. Global Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Drug
      1. Axicabtagene Ciloleucel
      2. Brexucabtagene Autoleucel
      3. Ciltacabtagene Autoleucel
      4. Sipuleucel-T
      5. Idecabtagene Vicleucel
      6. Lisocabtagene Maraleucel
      7. Tisagenlecleucel
      8. Lifileucel
      9. Others
   2. Market Analysis, Insights and Forecast – By Indication
      1. Lymphoma
      2. Myeloma
      3. Leukemia
      4. Others
   3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Oncology Treatment Centers
   4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
6. North America Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Drug
      1. Axicabtagene Ciloleucel
      2. Brexucabtagene Autoleucel
      3. Ciltacabtagene Autoleucel
      4. Sipuleucel-T
      5. Idecabtagene Vicleucel
      6. Lisocabtagene Maraleucel
      7. Tisagenlecleucel
      8. Lifileucel
      9. Others
   2. Market Analysis, Insights and Forecast – By Indication
      1. Lymphoma
      2. Myeloma
      3. Leukemia
      4. Others
   3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Oncology Treatment Centers
   4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
7. Europe Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Drug
      1. Axicabtagene Ciloleucel
      2. Brexucabtagene Autoleucel
      3. Ciltacabtagene Autoleucel
      4. Sipuleucel-T
      5. Idecabtagene Vicleucel
      6. Lisocabtagene Maraleucel
      7. Tisagenlecleucel
      8. Lifileucel
      9. Others
   2. Market Analysis, Insights and Forecast – By Indication
      1. Lymphoma
      2. Myeloma
      3. Leukemia
      4. Others
   3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Oncology Treatment Centers
   4. Market Analysis, Insights and Forecast – By County/ Sub-region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
8. Asia Pacific Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Drug
      1. Axicabtagene Ciloleucel
      2. Brexucabtagene Autoleucel
      3. Ciltacabtagene Autoleucel
      4. Sipuleucel-T
      5. Idecabtagene Vicleucel
      6. Lisocabtagene Maraleucel
      7. Tisagenlecleucel
      8. Lifileucel
      9. Others
   2. Market Analysis, Insights and Forecast – By Indication
      1. Lymphoma
      2. Myeloma
      3. Leukemia
      4. Others
   3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Oncology Treatment Centers
   4. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
9. Latin America Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Drug
      1. Axicabtagene Ciloleucel
      2. Brexucabtagene Autoleucel
      3. Ciltacabtagene Autoleucel
      4. Sipuleucel-T
      5. Idecabtagene Vicleucel
      6. Lisocabtagene Maraleucel
      7. Tisagenlecleucel
      8. Lifileucel
      9. Others
   2. Market Analysis, Insights and Forecast – By Indication
      1. Lymphoma
      2. Myeloma
      3. Leukemia
      4. Others
   3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Oncology Treatment Centers
   4. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
10. Middle East & Africa Immune Cell Therapy Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug
       1. Axicabtagene Ciloleucel
       2. Brexucabtagene Autoleucel
       3. Ciltacabtagene Autoleucel
       4. Sipuleucel-T
       5. Idecabtagene Vicleucel
       6. Lisocabtagene Maraleucel
       7. Tisagenlecleucel
       8. Lifileucel
       9. Others
    2. Market Analysis, Insights and Forecast – By Indication
       1. Lymphoma
       2. Myeloma
       3. Leukemia
       4. Others
    3. Market Analysis, Insights and Forecast – By End-user
       1. Hospitals
       2. Oncology Treatment Centers
    4. Market Analysis, Insights and Forecast – By Country/ Sub-region
       1. South Africa
       2. GCC
       3. Rest of Middle East & Africa
11. Competitive Analysis
    1. Global Market Share Analysis (2023)
    2. Company Profiles
       1. Gilead Sciences, Inc. (U.S.)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       2. Dendreon Pharmaceuticals LLC. (U.S.)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       3. Ferring (Switzerland)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       4. IOVANCE Biotherapeutics, Inc. (U.S.)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       5. Bristol Myers Squibb company (U.S.)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       6. Johnson & Johnson Services, Inc. (U.S.)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       7. Novartis AG (Switzerland)
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. Financials (Based on Availability) 
       8. Other Prominent Players